Outcomes of AL-amyloidosis treatment with bortezomib, dexamethasone and cyclophosphamide or doxorubicin-containing regimens

Česká verzia

Authors: Z. Adam ¹; M. Štork ¹; L. Pour ¹; M. Krejčí ¹; L. Zahradová ¹; V. Sandecká ¹; R. Hájek ¹; Z. Čermáková ²; Y. Pospíšilová ¹; M. Navrátil ¹; Z. Král ¹; J. Mayer ¹
Authors place of work: Interní hematologická a onkologická klinika Lékařské fakulty MU a FN Brno, pracoviště Bohunice, přednosta prof. MUDr. Jiří Mayer, CSc. ¹; Oddělení klinické biochemie FN Brno, pracoviště Bohunice, přednosta doc. MUDr. Milan Dastych, CSc., MBA ²
Published in the journal: Vnitř Lék 2012; 58(12): 896-903
Category: Original Contributions

Summary

According to the criteria for multiple myeloma, systemic AL–amyloidosis may be divided into primary systemic AL–amyloidosis, where monoclonal gametopathy is present but the criteria for multiple myeloma are not satisfied, and systemic AL–amyloidosis with underlying multiple myeloma. There is a continuous transition between the two units. The present paper describes treatment of patients with established systemic AL–amyloidosis who satisfy the 2003 International Myeloma Working Group’s criteria for symptomatic multiple myeloma (confirmed monoclonal immunoglobulin, clonal plasmocytes confirmed in the bone marrow and at least one clinical symptom of myeloma – confirmed amyloid). From 2009, a total of 10 patients with AL–amyloidosis and underlying multiple myeloma have been treated at our centre with combined bortezomib–containing regimens. The cohort includes 5 women and 5 men. Median age of these AL–amyloidosis patients at the diagnosis was 65.5 years. All 10 patients were treated with a combination of 3 drugs, bortezomib, cyclophosphamide and dexamethasone or bortezomib, doxorubicin a dexamethasone. Two of the 10 patients died during the first month of treatment. Treatment response cannot be evaluated in these patients. Haematological treatment response was evaluable in 8 patients only. Monoclonal immunoglobulin disappearance with negative urine and serum immunofixation and normalization of free light chain immunoglobulins was observed in six of the 8 patients. Treatment response according to the current IMWG was evaluated as very good partial remission (VGPR) as we did not perform bone marrow testing after the treatment to confirm complete remission according to the current criteria. One of the 8 evaluated patients died due to disease progression in the third month of treatment and there was no haematological treatment response in one who was considered to have a stable disease. Organ treatment response was evaluated in patients who were followed up for longer than 3 months of treatment only. Organ treatment response (reduced cardiac impairment) was not evaluable in a patient who had heart transplantation and then received chemotherapy. A total of 5 (83%) of the 6 evaluated patients fulfilled the criteria of organ treatment response.

Conclusion:
Our small cohort showed a high number of haematological treatment responses (VGPR in 75% of patients) as well as organ treatment response in patients with systemic AL–amyloidosis who were treated with bortezomib–containing treatment regimens.

Key words:
AL-amyloidosis - multiple myeloma - bortezomib

Zdroje

1. Ščudla V, Pika T. Současné možnosti léčby systémové AL amyloidózy. Vnitř Lék 2009; 55 (Suppl 1): 77–87.

2. Merlini G, Bellotti V. Molecular mechanisms of amyloidosis. N Engl J Med 2003; 349: 583–596.

3. Adam Z, Ščudla V. Klinické projevy a diagnostika AL-amyloidózy a některých dalších typů amyloidóz. Vnitř Lék 2001; 47: 36–45.

4. Bauerová L, Honsová E, Ryšavá R, Povýšil C. Systemová amyloidóza v renalní biopsii. Čes Patol 2009; 45: 64–68.

5. Brychta T, Pařenica J, Zatočil T et al. Restriktivní karciomyopatie jako příznak primární amyloidózy. Vnitř Lék 2004; 50: 66–71.

6. Gregor P. Amyloidóza srdce. Vnitř Lék 2008; 54: 948–949.

7. Honsová E. How to improve diagnosis of systemic amyloidosis in clinical practice. Česk Patol 2009; 45: 85–87.

8. Jankovec Z, Rušavý Z, Tĕsínský P, Lacigová S. Systémová amyloidóza s postižením ledvin. Čas Lék Česk 1999; 138: 699–700.

9. Krejčí J. Amyloidóza srdce, podceňovaná hrozba? Vnitř Lék 2008; 54: 950–951.

10. Kroupa R, Dastych M, Šenkyřík M et al. Systémové amyloidóza s dominující klinickou manifestací v trávicím traktu. Vnitř Lék 2005; 51: 588–592.

11. Kuchyňka P, Paleček T, Šimek S et al. Izolovaná forma srdeční amyloidózy. Vnitř Lék 2008; 54: 1010–1013.

12. Mach J. Problémy léčby primární amyloidózy. Vnitř Lék 1995; 41: 286–287.

13. Ryšavá R, Špička I, , Merta M, Tesař V, Trněný M. Je současná léčba primární a sekundární amyloidózy efektivní. Čas Lék Česk 2003; 142: 370–372.

14. Ryšavá R. Amyloidóza ledvin. Postgrad Med 2006; 8: 207–212.

15. Ryšavá R. Léčba paraproteinemické nefropatie a primární amyloidózy ledvin. Aktual Nefrol 2005; 11: 62–65.

16. Špička I, Merta M, Cieslar P et al. Poškození ledvin u monoklonální gamapatie. Čas Lék Česk 1995; 134: 478–481.

17. Šroubková R, Meisnerová E, Vítková I. Vzácné příčiny malabsorbčního syndromu. Čas Lék Česk 2003; 142: 300–302.

18. Tichý M. Primární amyloidóza. Lék Zpr UK Hradec Králové 1999; 44: 99–107.

19. Tošovský M, Soukup T, Bradna P et al. Myopatie a hyperlipoproteinemie jako první příznak systémové AL-amyloidózy. Vnitř Lék 2008; 54: 1014–1019.

20. Adam Z, Elleder M, Moulis M et al. Přínost PET-CT pro rozhodování o léčbě lokalizované nodulární plicní formy AL-amyloidosy. Vnitř Lék 2012; 58: 241–252.

21. Adam Z, Ščudla V, Tomíška M. Léčba AL--amyloidózy and některých dalších typů amyloidóz. Vnitř Lék 2001; 47: 46–52.

22. Sitia R, Palladini G, Merlini G. Bortezomib in the treatment of AL amyloidosis: targeted therapy? Haematologica 2007; 92: 1302–1307.

23. International Myeloma Working Group. Criteria for the classification of monoclonal gammopathies, multiple myelom and releated disorders: a report of the International Myeloma Working Group. Brit J Haematol 2003; 121: 749–457.

24. Kyle RA. Rajkumar SV. Criteria for diagnosis, staging, risk stratification and response assessment of multiple myeloma. Leukemia 2009; 23: 3–9.

25. Gertz MA, Comenzo R, Falk RH. Definition of organ involvement and treatment response in immunoglobulin light chain amyloidosis. A consensus opinion from the 10^th international symposium on amyloid and amyloidosis, Tours, France, 18-22 April 2004. Amer J Hematol 2005; 79: 319–328.

26. Ščudla V, Minařík J, Schneiderka P et al. Význam sérových hladin volných lehkých řetězců imunoglobulinu v diagnostice a hodnocení aktivity mnohočetného myelomu a vybraných monoklonálních gamapatií. Vnitř Lék 2005; 51: 1249–1259.

27. Kastritis E, Anagnostopoulos A, Roussou M et al. Treatment of light chain deposition disease with the combination of bortezomibe and dexamethasone. Blood 2007; 110 (N.11 Suppl.): abstr. 64.

28. Kastritis E, Anagnostopoulos A, Roussou M et al. Treatment of light chain (AL) amyloidosis with the combination of bortezomib and dexamethasone. Haematologica 2007; 92: 1351–1358.

29. Reece DE, Sanchorawala V, Hegenbart U et al. Weekly and twice-weekly bortezomib in patients with systemic AL-amyloidosis: results of a phase 1 dose-escalation study. Blood 2009; 114: 1489–1497.

30. Wechalekar AD, Lachmann HJ, Offer, Hawkins PN, Gillmore JD. Efficacy of bortezomib in systemic AL amyloidosis with relapsed/refractory clonal disease. Haematologica 2008; 93: 295–298.

31. Kastritis E, Wechalekar AD, Dimopoulos H et al. Significant activity of bortezomib-based therapy in patients with primary systemic AL--amyloidosis. Blood 2008; 112: 321, abstr. 869.

32. Zonder JA, Sanchorawala V, Snyder RM et al. Melphalan, dexamethosone plus bortezomib induces hematologic and organ response in AL-amylolidosis with tolerable neurotoxicity. Blood 2009; 114: (Suppl. N 22): 310, abstr. 746.

33. Jimenez-Zepeda VH, Reeder CB, Mikhael JR et al. Cyclophophamide, bortezomib and dexamethasone induces rapid and complete response in patients with amyloidosis non eligible for peripheral stem cell transplant. Blood 2009; 114: (Suppl. N 22): 737, abstr. 1857.

34. Singh V, Saad A, Palmer J et al. Response to bortezomib based induction therapy in newly diagnosed light chain (AL) amyloidosis. Blood 2009; 114 (Suppl. N 22): 740, abstr. 1867.

35. Lamm W, Willenbacher W, Zojer N et al. Efficacy of the combination of bortezomib and dexamethasone in systemic AL amyloidosis. Blood 2009; 114: (Suppl. N 22): 1121, abstr. 2871.

36. Kastritis E, Anagnostopoulos A, Rossou M et al. Treatment of light chain (AL) amyloidosis with the combination of bortezomib and dexamethasone. Haematologica 2007; 92: 1351–1358.

37. Moscetti A, Saltarelli F, Bianchi MP et al. Quick response to bortezomib plus dexamethasone in a patient with AL amyloidosis in first relapse. Amyloid. 2011; 18: (Suppl 1): 147–149.

38. Abonour R, Kramer G, Suvannasankha A, Benson MD. Bortezomib (Velcade) treatment of AL amyloidosis: Indiana University experience. Amyloid 2011; 18: (Suppl 1): 146.

39. Coriu D, Badelita S, Talmaci R et al. Bortezomib in systemic AL amyloidosis: a single center experience. Amyloid 2011; 18: (Suppl 1): 143–145.

40. Landau H, Hassoun H, Bello C et al. Consolidation with bortezomib and dexamethasone following risk-adapted melphalan and stem cell transplant in systemic AL amyloidosis. Amyloid 2011; 18: (Suppl 1): 130–131.

41. Dimopoulos MA, Kastritis E. Bortezomib for AL amyloidosis: moving forward. Blood 2011; 118: 827–828.

42. Dubrey SW, Reece DE, Sanchorawala V et al. Velcade Can2007 Study Group. Bortezomib in a phase 1 trial for patients with relapsed AL amyloidosis: cardiac responses and overall effects. QJM 2011; 104: 957–970.

43. Reece DE, Hegenbart U, Sanchorawala V et al. Efficacy and safety of once-weekly and twice-weekly bortezomib in patients with relapsed systemic AL amyloidosis results of a phase 1/2 study. Blood 2011; 118: 865–873.

44. Palladini G, Foli A, Russo P et al. Treatment of IgM-associated AL amyloidosis with the combination of rituximab, bortezomib, and dexamethasone. Clin Lymphoma Myeloma Leuk 2011; 11: 143–145.

45. Palladini G, Merlini G. Transplantation vs. conventional-dose therapy for amyloidosis. Curr Opin Oncol 2011; 23: 214–220.

46. Lamm W, Willenbacher W, Lang A et al. Efficacy of the combination of bortezomib and dexamethasone in systemic AL amyloidosis. Ann Hematol 2011; 90: 201–206.

47. Gertz MA, Zeldenrust SR. Treatment of immunoglobulin light chain amyloidosis. Curr Hematol Malig Rep 2009; 4: 91–98.

48. Ghose A, Tariq Z, Taj A, Chaudhary R. Acute dyspnea from treatment of AL amyloidisis with bortezomib. Am J Ther 2011; 18: e123–e125.

49. Michael M, Kastritis E, Delimpassi S et al. Greek Myeloma Study Group. Clinical characteristics and outcome of primary systemic light--chain amyloidosis in Greece. Clin Lymphoma Myeloma Leuk 2010; 10: 56–61.

50. Kastritis E, Wechalekar AD, Dimopoulos MA et al. Bortezomib with or without dexamethasone in primary systemic (light chain) amyloidosis. J Clin Oncol 2010; 28: 1031–1037.

51. Shah AD, Watts AJ, Mehta AB, Wechalekar AD. An unusual case of transient dermatological reaction to bortezomib in AL amyloidosis. Int J Hematol 2010; 91: 121–123.

52. Ščudla V, Minařík J, Pika T. Light chain deposition disease. Vnitř Lék 2012; 58: 38–43.

53. Minařík J, Šcudla V, Tichý T et al. Induction treatment of light chain deposition disease with bortezomib: rapid hematological response with persistence of renal involvement. Leuk Lymphoma 2012; 53: 330–331.

54. Issa ZA, Zantout MS, Azar ST. Multiple myeloma and diabetes. ISRN Endocrinol 2011; 2011: 815013.

55. Pospíšilová Y, Adam Z. Poruchy glukózového metabolizmu a regulace u pacientů s mnohočetným myelomem, kteří jsou léčeni vysokými dávkami glukokortikoidů na naší klinice. Vnitř Lék 2007; 53: 18–23.

56. Pathak RD, Jayaraj K, Blonde L. Thalidomide-associated hyperglycemia and diabetes: case report and review of literature. Diabetes Care 2003; 26: 1322–1323.

57. Volgi JR, Baldwin jr. D Glucocorticoid therapy and diabetes management. Nurs Clin North Am 2001; 36: 333–339.

58. Ščudla V, Petrová P, Minařík J, Pika T, Bačovský J. Analysis of the serum levels of selected biological parameters in monoclonal gammopathy of undetermined significance and different stages of multiple myeloma. Neoplasma 2011; 58: 499–506.

59. Ščudla V, Heřman M, Minařík J et al. Přínos celotělové magnetické rezonance pro diagnózu monoklonalní gamapatie nejistého významu, mnohočetného myelomu a vyšetření Durie-Salmon Plus staging systému. Vnitř Lék 2011; 57: 52–60.

60. Mysliveček M, Bačovský J, Ščudla V et al. 18F-FDG PET/CT a 99mTc-MIBI scintigrafie při hodnocení pacientů s mnohočetným myelomem a s monoklonální gamapatií nejistého významu. Klin Onkol 2010; 23: 325–331.

61. Ščudla V, Budíková M, Petrová P et al. Analýza sérových hladin vybraných biologických parametrů u monoklonální gamapatie a mnohočetného myelomu. Klin Onkol 2010; 23: 171–181.

62. Ščudla V, Pika T, Budíková M et al. The importance of serum levels of selected biological parameters in the diagnosis, staging and prognosis of multiple myeloma. Neoplasma 2010; 57: 102–110.

63. Pika T, Minařík J, Schneiderka P et al. The correlation of serum immunoglobulin free light chain levels and selected biological markers in multiple myeloma. Biomed Pap Med Fac Univ Palacky Olomouc Czech Repub 2008; 152: 61–64.

64. Vytřasová M, Ščudla V, Nekula J et al. Magnetická rezonance při vyšetření páteře u mnohočetného myelomu.Vnitř Lék 2001; 47: 694–698.